Pharma & MedTech Research
KOL Identification & Mapping in Pharma & MedTech: Importance, Practices, and Impact
To assess how important KOL identification and mapping are for pharmaceutical and medtech companies, and to understand:
Sample size
50
Regions
US 52% | EU 48%
Objective
To assess how important KOL identification and mapping are for pharmaceutical and medtech companies, and to understand:
- Current approaches and tools used
- Perceived business impact (clinical, commercial, market access)
- Regional differences (US vs EU)
- Gaps and unmet needs
Expected Outcomes
From ~50 respondents, you should be able to:
- Quantify importance level (strategic vs operational)
- Identify common KOL identification methods (manual vs AI-driven)
- Measure impact on decision-making (trial design, product adoption, etc.)
- Understand challenges (data quality, compliance, fragmentation)
- Compare US vs EU trends
- Segment responses by role (Medical Affairs, Commercial, R&D)
Target Respondents
- Medical Affairs leaders
- Commercial/Marketing heads
- Clinical development professionals
- Market access teams
- United States
- European Union (major markets: Germany, France, UK, Italy, Spain)
Study Overview
Sample size
50
Regions
US (52%), EU (48%)
Industries
Pharma (60%), MedTech (30%), Both (10%)
Q1. Role & Organization Type
| Role | % Response |
|---|---|
| Medical Affairs | 32% |
| Commercial/Marketing | 24% |
| Clinical Development | 18% |
| Market Access | 16% |
| Other | 10% |
| Organization Type | % Response |
|---|---|
| Pharma | 60% |
| MedTech | 30% |
| Both | 10% |
Q2. Importance of KOL Identification
| Importance Level | % Response |
|---|---|
| Extremely important | 46% |
| Very important | 34% |
| Moderately important | 14% |
| Slightly important | 4% |
| Not important | 2% |
Insight: 80% consider KOL mapping highly strategic.
Q3. Primary Use Cases (Top 3 selections)
| Use Case | % Respondents Selecting |
|---|---|
| Clinical trial design & recruitment | 58% |
| Advisory boards | 52% |
| Product launch strategy | 48% |
| Scientific communication | 44% |
| Market access & payer engagement | 36% |
| Competitive intelligence | 28% |
Insight: Strong tilt toward clinical and launch excellence.
Q4. Current Methods Used
| Method | % Response |
|---|---|
| Internal databases/manual research | 64% |
| Third-party vendors | 56% |
| Publication & congress tracking | 50% |
| AI/analytics platforms | 38% |
| Social media/digital opinion leaders | 26% |
Insight: Traditional methods still dominate; AI adoption is emerging.
Q5. Effectiveness of Current Approach
| Effectiveness Level | % Response |
|---|---|
| Very effective | 18% |
| Effective | 42% |
| Neutral | 20% |
| Ineffective | 16% |
| Very ineffective | 4% |
Insight: Only 60% satisfied → clear room for improvement.
Q6. Key Challenges (Top 3 selections)
| Challenge | % Respondents Selecting |
|---|---|
| Data fragmentation | 62% |
| Outdated information | 54% |
| Lack of global visibility | 46% |
| Difficulty measuring influence | 42% |
| Compliance/regulatory issues | 34% |
| Limited technology/tools | 30% |
Insight: Data quality + integration are the biggest barriers.
Q7. Impact on Business Outcomes
Q7A. Clinical Trial Success
Strong impact: 48%, Moderate impact: 34%, Low impact: 12%, No impact: 6%.
Q7B. Speed of Product Adoption
Strong impact: 44%, Moderate impact: 38%, Low impact: 12%, No impact: 6%.
Q7C. Market Access Success
Strong impact: 40%, Moderate impact: 36%, Low impact: 16%, No impact: 8%.
Q7D. HCP Engagement Quality
Strong impact: 52%, Moderate impact: 32%, Low impact: 10%, No impact: 6%.
Insight: Highest perceived impact is on HCP engagement and clinical success.
Q8. Future Investment & Trends
| Investment Outlook | % Response |
|---|---|
| Increase significantly | 36% |
| Increase moderately | 40% |
| Stay the same | 18% |
| Decrease | 6% |
Q8B. Desired Improvements (Open-ended summarized)
| Theme | % Mentions |
|---|---|
| Better data integration | 58% |
| Real-time KOL insights | 46% |
| AI-driven identification | 42% |
| Global coverage | 38% |
| Compliance-friendly tools | 30% |
Key Study Conclusions
1. Strategic Importance is High
4 out of 5 respondents view KOL mapping as critical
2. Traditional Methods Still Dominate
Heavy reliance on manual + vendor-driven approaches. AI adoption is growing but not mainstream
3. Data Challenges are the Biggest Bottleneck
Fragmentation and outdated info limit effectiveness
4. Strong Business Impact
Especially in HCP engagement, clinical trials, and product adoption
5. Investment is Increasing
76% expect higher spending → strong growth area
